United Therapeutics Corporation (Nasdaq: UTHR) has acquired Thymmune Therapeutics, Inc., a privately held, preclinical-stage biotechnology company developing iPSC-derived thymic cell therapies, for up to USD 300 million in total consideration. The US-based transaction extends United Therapeutics' organ manufacturing and immunomodulatory platform into thymic regenerative medicine, directly complementing its existing UThymoKidney clinical development program.
Under the terms of the agreement, United Therapeutics paid USD 140 million in cash upfront, subject to certain post-closing adjustments, and may pay former Thymmune equityholders up to an additional USD 160 million contingent on the achievement of defined clinical and regulatory milestones by the end of 2031. No royalty terms or equity components were disclosed. The deal is structured as a full acquisition, with United Therapeutics acquiring worldwide rights to all Thymmune assets. Financial terms beyond the upfront and earn-out structure were not disclosed.
Thymmune's lead candidate, THY-100, is in preclinical development for congenital athymia, an ultra-rare condition in which infants are born without a functional thymus, leaving them unable to develop normal T-cell immunity. Thymmune's proprietary platform converts human induced pluripotent stem cells (iPSC) into thymic epithelial cells that, once transplanted, mature in vivo and support neo-thymus formation capable of facilitating T-cell development. Animal studies reported by the company indicated that THY-100 treatment resulted in the formation of a functional neo-thymus in vivo.
The only currently approved therapy for congenital athymia is thymus tissue implantation (Rethymic), derived from processed human donor thymus; THY-100's iPSC-derived approach is designed to offer a scalable, non-donor-dependent alternative. Broader commercial interest in iPSC-derived cell therapy manufacturing infrastructure has grown substantially, reflecting the sector's recognition that scalable iPSC production is a prerequisite for commercial viability of such platforms.